• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

    2/6/23 8:10:00 AM ET
    $ISR
    Medical Specialities
    Health Care
    Get the next $ISR alert in real time by email

    The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals

    Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies' focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites. Viewpoint Molecular Targeting CEO Thijs Spoor has been named Chief Executive Officer and outgoing Isoray CEO Lori Woods assumed the role of Chairperson of the Board of Directors of the combined companies. The closing of the all-stock transaction became effective on February 3, 2023.

    Outgoing Isoray CEO Lori Woods said, "This merger represents an important milestone for Isoray. The merger with Viewpoint Molecular Targeting demonstrates our commitment to build on our shared belief of treating cancers from the inside out while providing personalized targeted treatment options for cancer patients. We look forward to delivering a path forward that speaks to the continued growth of the combined companies benefitting patients and the doctors who treat them, while increasing stockholder value."

    Incoming Isoray CEO Thijs Spoor commented, "The merger of Isoray and Viewpoint represents a powerful combination of two complementary businesses in the field of radiopharmaceuticals. The mission of the combined company is to further develop the role of Cesium-131 for the treatment of a variety of cancers while we expand on our exciting and novel pipeline of proprietary targeting peptides to diagnose tumors in order to deliver powerful Targeted Alpha Therapies (TAT's). The use of alpha-particle radiation with proprietary targeted delivery agents has the potential to transform the treatment paradigm of patients suffering from early stage cancers."

    About the Merger

    At the closing of the merger, each issued and outstanding share of common stock of Viewpoint was converted into 3.1642 shares of Isoray common stock for a total of 136,545,075 shares, or approximately 49%, of the 278,657,841 shares of outstanding common stock of Isoray. Other than cash paid in lieu of fractional shares which amounted to $14.80, there was no cash consideration paid in connection with the merger.

    Concurrent with the closing of the merger, the size of Isoray's Board of Directors was increased to five members comprised of Lori Woods (Chairperson), Thijs Spoor, Dr. Frank Morich, Robert Williamson, and Michael McCormick.

    About Isoray

    Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and Twitter.

    About Viewpoint Molecular Targeting

    Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company's proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

    The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company's website www.viewpointmt.com.

    Safe Harbor Statement

    Statements in this news release about Isoray's future expectations, including those regarding the anticipated synergies and benefits of the merger with Viewpoint Molecular Targeting, Inc., and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether and to what extent the anticipated benefits of the merger are realized; the ability of Isoray to manage growth and successfully integrate its business with Viewpoint; whether Isoray and Viewpoint can maintain their key employees; the ability to raise ongoing capital to fund added costs of research and development related to the Viewpoint business; the risk that the merger disrupts current plans and operations; the outcome of any legal proceedings that may be instituted against Isoray and/or Viewpoint following consummation of the merger; and other risks detailed from time to time in Isoray's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005219/en/

    Get the next $ISR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISR

    DatePrice TargetRatingAnalyst
    9/14/2021$1.25Outperform
    Northland Capital Markets
    More analyst ratings

    $ISR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    2/1/24 4:53:13 PM ET
    $ISR
    Medical Specialities
    Health Care

    Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/30/24 4:57:17 PM ET
    $ISR
    Medical Specialities
    Health Care

    Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/26/24 5:40:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Initial Results From First Patient Dosed With Perspective Therapeutics' Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

    RICHLAND, Wash. & CORALVILLE, Iowa, Feb. 22, 2023 (GLOBE NEWSWIRE) --  Perspective, Therapeutics, Inc. (formerly known as "Isoray, Inc.") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis. Dr Vikas Prasad presented the results at the 2023 PET Radiotracer Translation and Resource Center (PET-RTRC) Work

    2/22/23 5:02:57 PM ET
    $CATX
    $ISR
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

    RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

    2/16/23 4:05:02 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

    Company's focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately. Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its

    2/7/23 5:48:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    2/1/24 4:53:13 PM ET
    $ISR
    Medical Specialities
    Health Care

    Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/30/24 4:57:17 PM ET
    $ISR
    Medical Specialities
    Health Care

    Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    1/26/24 5:40:04 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    SEC Filings

    View All

    IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    2/5/24 4:34:33 PM ET
    $ISR
    Medical Specialities
    Health Care

    SEC Form D filed by IsoRay Inc.

    D - Perspective Therapeutics, Inc. (0000728387) (Filer)

    1/22/24 4:17:28 PM ET
    $ISR
    Medical Specialities
    Health Care

    IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

    1/22/24 4:10:45 PM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital Markets initiated coverage on Isoray with a new price target

    Northland Capital Markets initiated coverage of Isoray with a rating of Outperform and set a new price target of $1.25

    9/14/21 8:21:18 AM ET
    $ISR
    Medical Specialities
    Health Care

    Lake Street initiated coverage on IsoRay with a new price target

    Lake Street initiated coverage of IsoRay with a rating of Buy and set a new price target of $3.00

    2/18/21 8:47:05 AM ET
    $ISR
    Medical Specialities
    Health Care

    HC Wainwright & Co. reiterated coverage on Isoray with a new price target

    HC Wainwright & Co. reiterated coverage of Isoray with a rating of Buy and set a new price target of $2.10 from $1.25 previously

    2/10/21 6:11:10 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Leadership Updates

    Live Leadership Updates

    View All

    Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

    RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort's appointment adds key expertise. "I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray." Woods concluded, "We believe Donna's proven d

    4/13/21 8:13:00 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Financials

    Live finance-specific insights

    View All

    Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

    RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

    2/16/23 4:05:02 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

    RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. "The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders. It provides us with the opportunity to build on Isoray's existing business with a pipeline of very

    11/10/22 4:05:00 PM ET
    $ISR
    Medical Specialities
    Health Care

    Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

    RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022. To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002

    10/31/22 8:14:00 AM ET
    $ISR
    Medical Specialities
    Health Care

    $ISR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IsoRay Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    9/18/23 9:20:56 PM ET
    $ISR
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by IsoRay Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    9/18/23 8:02:56 PM ET
    $ISR
    Medical Specialities
    Health Care